Mark Nuijten is medical doctor, health economist, market access and pricing consultant, valuation economist,  and healthcare policy journalist.  Mark Nuijten has a varied career in the health academic and business environment.  He is pursuing development of economic modelling and broadening its application in health care and finance. His reimbursement dossiers, incl. cost-effectiveness and BIA models, successfully contributed to positive reimbursement decisions by health authorities in many countries, (for example, NICE in England, SMC in Scotland, TLV in Sweden, CADTH in Canada, Zin in The Netherlands, RIZIV/INMAI in Belgium).

He is academic supervisor of PhD programs at the Universities of Maastricht and Groningen in The Netherlands and founder of the ISPOR Special Interest Group on nutrition-economics. Since 2017 he is Adjunct Professor at ITU (Istanbul Technical University) in International Healthcare Assessment and Valuation.

Lina graduated with a Master’s degree in Pharmaceutical Sciences from the Université libre de Bruxelles (ULB) in Belgium. She completed her master thesis with a “magna cum laude” in the field of digital health. The subject of the thesis was “The Introduction of Innovative Digital Health Technologies in the Belgian Healthcare System – A comparison with other European Healthcare Systems.” This master thesis focuses on three aspects regarding the introduction of digital health technologies, more specifically the implementation of Electronic Health Records, Telemedicine and Mobile apps within the healthcare system of Belgium, France and Germany. It also included a description of the new initiatives presented by the European commission regarding the European Health Data Space. Lina was an intern for a year and a half within the Health Economic & Market Access department of one of the top 10 global pharmaceutical companies within the Medical Devices division. She also holds a Specialized Master in Entrepreneurship and Innovation from Rome Business School. Lina joined Vivactis Market Access in May 2023.

Christine Juliam started her career in clinical research at MSD in Belgium before moving into product management, and subsequently into sales, marketing, and business planning responsibilities. In July 1996, she started to work for Abbott Belgium as director of the pharmaceutical product division, and joined Nycomed as managing director Belgium/Luxembourg in 2006. From 2011 onwards, she was region head for France, the Netherlands, Belgium, and Luxembourg for Nycomed, which was acquired by Takeda in the same year. Subsequently, Ms. Juliam managed Takeda Italy and France as country manager between 2013 and 2017. In 2021-2022, she was general manager at Orifarm. Christine Juliam has a Doctor’s Degree of Medicine from the University of Ghent, a License in Marketing from St. Aloysius College in Brussels, a Master in Management from Solvay Commercial School in Brussels, and an MBA from Northwestern University.